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Abstract
Ebolaviruses, marburgviruses, and henipaviruses are zoonotic pathogens belonging to the 
Filoviridae and Paramyxoviridae families. They exemplify viruses that continue to spill over into 
the human population, causing outbreaks characterized by high mortality and significant clinical 
sequelae in survivors of infection. There are currently no approved small molecule therapeutics for 
use in humans against these viruses. In this study, we evaluated the antiviral activity of the 
nucleoside analog 4′-azidocytidine (4′N3-C, R1479) and its 2′-monofluoro- and 2′-difluoro-
modified analogs (2′F-4′N3-C and 2′diF-4′N3-C) against representative paramyxoviruses (Nipah 
virus, Hendra virus, measles virus, and human parainfluenza virus 3) and filoviruses (Ebola virus, 
Sudan virus, and Ravn virus). We observed enhanced antiviral activity against paramyxoviruses 
with both 2′diF-4′N3-C and 2′F-4′N3-C compared to R1479. On the other hand, while R1479 
and 2′diF-4′N3-C inhibited filoviruses similarly to paramyxoviruses, we observed 10-fold lower 
filovirus inhibition by 2′F-4′N3-C. To our knowledge, this is the first study to compare the 
susceptibility of paramyxoviruses and filoviruses to R1479 and its 2′-fluoro-modified analogs. 
The activity of these compounds against negative-strand RNA viruses endorses the development of 
4′-modified nucleoside analogs as broad-spectrum therapeutics against zoonotic viruses of public 
health importance.
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1. INTRODUCTION
In the decades prior to 2014, human outbreaks of emerging zoonotic virus causing fatal 
hemorrhagic fever, such as Ebola virus (EBOV), or encephalitis, such as Nipah virus (NiV), 
have been relatively sporadic and small in terms of case numbers, ranging from isolated 
single cases to several hundred cases (CDC, 2017; Luby and Gurley, 2012). The historically 
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largest EBOV outbreak of 2013–2016 highlighted the relative paucity of efficacious 
therapeutics and vaccines available to deploy against such pathogens, despite extensive pre-
clinical studies demonstrating efficacy of therapeutic antibodies and vaccines for these 
biosafety level-4 pathogens (Broder et al., 2016; Geisbert et al., 2014; Mendoza et al., 2017; 
Mire et al., 2016; Qiu et al., 2014). To identify therapeutics that could be repurposed against 
EBOV, in vitro screens of libraries of FDA-approved compounds have been conducted, 
screening, among others, antiviral nucleoside and nucleotide analogs (Madrid et al., 2015; 
Veljkovic et al., 2015; Welch et al., 2016). Over the last 30 years, the development of 
antiviral nucleoside and nucleotide analogs was primarily directed towards combating 
viruses responsible for chronic infections such as human immunodeficiency virus, herpes 
viruses, and hepatitis viruses (Ray and Hitchcock, 2009). In 2006, Klumpp and colleagues 
first demonstrated the in vitro activity of 4′-azidocytidine (4′N3-C, R1479) against hepatitis 
C virus (HCV), a single-stranded, positive-sense RNA virus (Klumpp et al., 2006). The 
development of R1479 and its prodrug balapiravir was halted following findings of toxicity 
and low efficacy of these compounds in clinical trials for treating HCV and Dengue virus 
(Nelson et al., 2012; Nguyen et al., 2013). Despite this, the in vitro activity of R1479 against 
diverse flaviviruses of public health importance, such as Dengue virus and tick-borne 
encephalitis virus, suggested that it may be a template for developing modified analogs with 
antiviral activity (Chen et al., 2014; Eyer et al., 2016). Interestingly, R1479 and other 4′-
modified analogs have recently been shown to also inhibit respiratory syncytial virus (RSV), 
a single-stranded, negative-sense RNA virus (Clarke et al., 2015; Deval et al., 2015; Wang et 
al., 2015). Following those studies, we described potent antiviral activity of R1479 against 
representative members of the Paramyxoviridae family, including the henipaviruses, NiV 
and Hendra virus (HeV) (Hotard et al., 2017). Given the in vitro antiviral properties of 
R1479 and its 2′-mono and 2′-difluoro analogs (2′F-4′N3-C and 2′diF-4′N3-C, 
respectively) against RSV (Deval et al., 2015), and the highly conserved nucleotide binding 
domains shared across Pneumoviridae, Paramyxoviridae, and Filoviridae families (Lo et al., 
2017), we evaluated and compared the antiviral potencies of these cytidine analogs against 
representative paramyxoviruses and filoviruses including the 2014 Makona variant of EBOV 
(Albarino et al., 2015). Our study documents the susceptibility of paramyxoviruses and 
filoviruses to R1479 and its 2′-fluoro-modified analogs, and reinforces the prospect of 
developing 4′-modified nucleoside analogs as potential broad-spectrum therapeutics against 
RNA viruses of public health importance.
2. MATERIALS AND METHODS
2.1 Biosafety
All work with infectious virus was performed in Class 2 Biosafety cabinets, and all work 
utilizing live Nipah virus (NiV), Hendra virus (HeV), Ebola virus (EBOV), Sudan virus 
(SUDV), Ravn virus (RAVV), Marburg virus (MARV), and Rift Valley Fever virus (RVFV) 
was conducted in a BSL-4 laboratory at the Centers for Disease Control and Prevention 
(CDC; Atlanta, GA).
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2.2 Cells, viruses, and compounds
HeLa, SK-N-MC, and NCI-H358 cells were purchased from the American Type Tissue 
Culture Collection (ATCC, Manassas, VA, USA). HeLa and SK-N-MC cells were 
propagated in Dulbecco’s modified Eagle medium (DMEM; Life Technologies, Carlsbad, 
CA, USA) supplemented with 10% (vol/vol) fetal calf serum (FCS; Hyclone; Thermo 
Scientific, Waltham, MA, USA) and penicillin-streptomycin (Life Technologies). NCI-H358 
cells were propagated in Roswell Park Memorial Institute medium (RPMI 1640), 
supplemented with 10% FCS. Huh7 cells were obtained from Apath, LLC (Brooklyn, NY, 
USA), and propagated in DMEM supplemented with 10% FCS and 1× nonessential amino 
acids (Life Technologies). Normal human small airway epithelial cells (SAECs) were 
purchased from ATCC and propagated in Airway Epithelial Cell Basal medium 
supplemented with the Bronchial Epithelial Cell Growth Kit (ATCC).
NiV (Malaysian genotype), recombinant NiV Malaysian genotype expressing ZsGreen1 
fluorescent protein (NiV-GFP2AM) (Lo et al., 2014), HeV, recombinant Measles virus (MV) 
(Edmonston-Zagreb strain) expressing enhanced green fluorescent protein) 
(rMVEZEGFP(3)) (Rennick et al., 2015), EBOV (Makona variant), recombinant EBOV 
(Mayinga variant) (representative of Ebolavirus genus), SUDV (Gulu variant) (Sanchez and 
Rollin, 2005), RAVV (Ravn variant) (Johnson et al., 1996), and recombinant RVFV 
expressing enhanced green fluorescent protein (RVFV-GFP, ZH501) (Bird et al., 2007) were 
propagated in either Vero E6 (ATCC CRL-1586) or Vero (ATCC CCL-81) cells, and were 
quantitated by 50% tissue culture infections dose (TCID50) assay using the Reed and 
Muench method (Reed and Muench, 1938). Recombinant EBOV Makona variant expressing 
ZsGreen1 (EBOV-ZsG) (Albarino et al., 2015) and recombinant MARV (Bat371 variant) 
expressing ZsGreen1 (MARV-ZsG) was propagated and quantitated as above using Huh7 
cells. Recombinant respiratory syncytial virus (RSV) expressing enhanced green fluorescent 
protein (rgRSV224) (Hallak et al., 2000) was propagated and quantitated as above using 
HeLa cells. Recombinant human parainfluenza virus 3 expressing enhanced green 
fluorescent protein (hPIV3-GFP) (JS strain) (Zhang et al., 2005) was obtained from ViraTree 
and was propagated and quantitated as above using Vero cells.
R1479, 2′F-4′N3-C, 2′diF-4′N3-C (Figure 1) and their corresponding triphosphates were 
synthesized at Alios BioPharma.
2.3 Single Nucleotide Incorporation by Recombinant RSV L-P
Recombinant RSV L-P was produced through the co-expression of RSV L and P proteins in 
a baculovirus expression system, according to previously described procedures (Noton et al., 
2012). The reaction mixture was composed of 0.2 μM modified template sequence 
(UGCGCUUGUUU), 0.2 μM recombinant RSV L-P polymerase, 200 μM 5′-pACGC 
primer, buffer (20 mM Tris pH 7.5, 10 mM KCl, 6 mM MgCl2, 2 mM DTT, 0.01% Triton, 
10% DMSO), and (α-33P)-GTP with a final volume of 10 μL. The reaction was started 
through the addition of NTPs, incubated at 30°C for 30 minutes, and quenched through the 
addition of gel loading buffer (Ambion). Samples were run for 1.5 hours at 80 W in a 22.5% 
polyacrylamide urea sequencing gel. The gel was then exposed to a phosphor-screen, and 
scanned.
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2.4 Measurement of Nucleoside Triphosphate (NTP) Formation
R1479 triphosphate (TP) formation was measured in HeLa, Huh7, SK-N-MC, and NCI-
H358 cells. 2′F-4′N3-CTP, and 2′diF-4′N3-CTP formation were measured in HeLa and 
NCI-H358 only. The cells were maintained and cultured at Alios BioPharma. The cells were 
seeded in six-well plates at 1.5 × 106 cells/well with their corresponding media and 
incubated overnight in a cell culture incubator at 37 °C and 5% CO2 before use. In the 
experiment, 50 μM of R1479, 2′F-4′N3-C, or 2′diF-4′N3-C was added to each well, 
incubated for 24 h at 37°C and 5% CO2. At the end of the incubation, the medium was 
removed and cells were washed twice with cold 0.9% sodium chloride in water. The cells 
were lysed with methanol/water (70%/30%, v/v), and the extracted supernatant was dried 
and reconstituted in 1 mM ammonium phosphate before LC/MS/MS analysis to determine 
the corresponding R1479-TP, 2′F-4′N3-CTP, and 2′diF-4′N3-CTP levels (Chen et al., 
2009). The concentrations of the R1479-TP, 2′F-4′N3-CTP, and 2′diF-4′N3-CTP were 
normalized by the number of cells and reported as picomoles per million cells.
2.5 Recombinant reporter virus assays
All viruses expressing fluorescent (GFP, ZsGreen) proteins were assayed for fluorescence by 
using an H1 Synergy plate reader (Biotek). NCI-H358 cells or SAECs were seeded at 2×104 
cells per well in black opaque 96-well plates (Corning 3619, Corning, NY) or Perkin-Elmer 
CellCarrier Ultra plates (Waltham, MA) and compounds were added to the assay plates for 1 
h. Assay plates were transferred to the BSL-4 suite (where appropriate), and infected with 
0.25–0.5 TCID50 per cell of the respective virus, and were read between 48 to 168 hours 
post-infection (hpi) depending on the virus used. Fluorescence signal from DMSO-treated 
infected cells were set as 100% GFP. 50% effective concentrations (EC50) were calculated 
using four-parameter variable slope non-linear regression fitting of mean values of assays 
performed in quadruplicate (Graphpad Prism 6, La Jolla, CA).
2.6 Cytopathic effect (CPE) inhibition and cell viability assays
NCI-H358 cells or SAECs were seeded at 2×104 cells per well in white opaque 96-well 
plates, and compounds were added to the assay plates. Assay plates were transferred to the 
BSL-4 suite and infected with 0.25–0.5 TCID50 per cell, and were analyzed with CellTiter-
Glo 2.0 (Promega, Madison, WI) between 72–96 h post-infection (pi) in a HD1 Synergy 
plate reader. Values were normalized to uninfected cell controls according to % viability as 
follows: % viability = [(specific value-reference value)/(DMSO control value – reference 
value)] × 100. Reference values were derived from control wells without cells. Uninfected 
cell control values (after subtraction of reference values) were set at 100% inhibition of 
CPE. EC50 values were calculated using four-parameter variable slope non-linear regression 
fitting of values. The CellTiter-Glo 2.0 assay was also used to determine viability of 
uninfected NCI-H358 cells treated with 3-fold serial dilutions of the compounds for 72 h (3 
days) or 168 h (7 days). Values were normalized to DMSO controls according to % viability 
as follows: % viability = [(specific value-reference value)/(DMSO control value – reference 
value)] × 100. Reference values were derived from control wells without cells. DMSO 
control values (after subtraction of reference values) were set at 100% viability. 50% 
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viability/cytotoxicity (CC50) values were calculated using four-parameter variable slope 
non-linear regression fitting of mean values derived from quadruplicate samples.
2.7 Quantitative Focus-forming unit (FFU) assay
To measure compound inhibition of filovirus infection and spread, 2×104 NCI-H358 cells or 
SAECs treated with compound were infected with 0.5 TCID50 of EBOV, SUDV, RAVV, or 
MARV-ZsG. At 7 days pi, cells were fixed in 10% formalin supplemented with 0.2% Triton-
X detergent, and stained with primary rabbit anti-EBOV polyclonal serum (1:2000), and 
after several washes the corresponding anti-rabbit Dylight 488 conjugated secondary 
antibody (Bethyl Laboratories, Bethesda, MD) was added (1:1000) for 1 h. After 3 washes, 
filovirus infection-induced focus forming units (FFU) were measured in each well of the 96-
well plate (CellCarrier-96, Perkin Elmer, Waltham, MA) using a Cytation5 cell imaging 
multi-mode reader paired with Gen5 software (Biotek, Winooski, VT). For MARV-ZsG, 
GFP+ cells were counted directly at 3 days pi without need for fixation and antibody 
staining. A 2.74× objective lens was used to take 12 overlapping images encompassing each 
entire well, which were assembled and then analyzed for FFUs ranging in size from 15–200 
μm, and which had a relative fluorescence signal that was above 2000. The camera gain was 
set at 15.6, with an integration time of 306 msec, using an LED intensity setting of 10. The 
average number of background cell counts were subtracted from each well to give 
normalized cells counts, and any negative values were adjusted to “0”. For analysis of each 
experimental replicate, the highest number of positive counts was regarded as 100%, while 0 
counts was used for 0% positivity. Following this normalization, data were fitted to a 4-
parameter variable slope non-linear regression fitting of mean values derived from 
quadruplicate samples.
2.8 Infectious virus yield reduction assays
To measure compound inhibition of infectious filovirus yield, 2×104 NCI-H358 cells were 
infected with 0.5 TCID50 of SUDV or RAVV per cell for 1 h. Virus inoculum was then 
removed, cells were washed once with phosphate buffered saline, and replaced with culture 
medium containing respective compound in a 10-point 3-fold dilution series. At 7 days pi, 
supernatants were harvested, serially diluted (10-fold) and mixed with 104 Vero cells per 
well in 96 well plates. At day 5 pi, plates were fixed with 10% formalin supplemented with 
0.2% Triton-X detergent, and stained with primary rabbit anti-EBOV serum, and after 
several washes the corresponding anti-rabbit Dylight 488 conjugated secondary antibody 
was added. Plates were visually assayed using a microscope for fluorescent cells, and 
quantitated by 50% tissue TCID50 assay using the Reed and Muench method (Reed and 
Muench, 1938). EC50 values were calculated using four-parameter variable slope non-linear 
regression fitting of mean values derived from quadruplicate samples. Similarly, to measure 
compound inhibition of infectious henipavirus yield, 2×104 NCI-H358 cells were infected 
with 0.25 TCID50 of NiV or HeV per cell for 1 h. Virus inoculum was then removed, cells 
were washed once with phosphate buffered saline, and replaced with culture medium 
containing compound in a 10-point 3-fold dilution series. At 48 h pi supernatants were 
harvested, serially diluted, and mixed with 104 Vero cells per well in 96-well plates. At day 
5 pi, plates were visually assayed for CPE, and then virus titers were quantitated by 50% 
tissue TCID50 assay using the Reed and Muench method (Reed and Muench, 1938). EC50 
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values were calculated using four-parameter variable slope non-linear regression fitting of 
mean values derived from quadruplicate samples.
3. RESULTS
3.1 Triphosphate forms of R1479 and its 2′-mono- and 2′-difluoro-modified analogs inhibit 
RSV polymerase activity by acting as RNA chain terminators
To confirm the antiviral mechanism of action of R1479 and its 2′-mono and 2′-difluoro-
modified analogs (depicted in Figure 1a, b, and c respectively), we first performed cell-free 
in vitro RSV polymerase assays. The RSV polymerase forms a dimer of the L and P protein 
(RSV L-P) that accepts RNA templates with a primer to generate short RNA synthesis 
products (Figure 1d) (Noton et al., 2012). RSV L-P extends the primer by 1 base with the 
addition of (α-33P)-GTP (Figure 1e, lane 1) and fully it extends by 7 bases with the addition 
of ATP and CTP (Figure 1e, lane 3). We individually substituted the 3 cytidine analogs in 
place of natural CTP to understand their potential effects as non-obligatory chain terminators 
in an RNA synthesis assay (Figure 1e, lanes 4–6). R1479-TP, 2′F-4′N3-CTP, and 
2′diF-4′N3-CTP terminated RNA synthesis by RSV L-P at position +8, and were 
recognized almost equally by the enzyme. This is consistent with observations of other 2′ 
and 4′-modified cytidine analogs that inhibit RSV polymerase in similar assays (Deval et al., 
2015).
3.2 Intracellular phosphorylation levels of R1479, 2′F-4′N3-C, and 2′diF-4′N3-C are highly 
dependent on cell type
In a previous study, we observed different levels of R1479 antiviral activity against 
henipaviruses depending on the cell line used, with consistently lower R1479 antiviral 
activity in HeLa cells than in a human epithelial lung carcinoma cell line (NCI-H358) 
(Hotard et al., 2017). To investigate whether this difference was due to cellular 
phosphorylation levels of R1479, we measured intracellular phosphorylation of R1479 in 4 
human cell lines: HeLa, a cervical adenocarcinoma line; Huh7, a hepatoma line; SK-N-MC, 
a neuroepithelioma line; and NCI-H358. Each cell line was treated with R1479 for 24 h, and 
intracellular triphosphate levels were then measured using tandem liquid chromatography/
mass spectrometry (LC/MS/MS) and quantitated using synthetic standards. Levels of the 
corresponding triphosphate (R1479-TP) were measured in each of the 4 cell lines, with 
highest R1479-TP levels seen in NCI-H358 cells (391 ± 72 pmol/million cells; Figure 2a). 
Phosphorylation of R1479 was lowest in Huh7 cells and SK-N-MC cells (18 ± 0.6 and 42 
± 10 pmol/million cells, respectively), and intermediate in HeLa cells (136 ± 21 pmol/
million cells). In addition to R1479, which contains a 4′-azido substitution, we examined the 
effects of 2′-monofluoro or 2′-difluoro substitutions on NTP levels using the 2 cell lines 
with the highest NTP levels. HeLa and NCI-H358 cells were treated with 2′F-4′N3-C and 
2′diF-4′N3-C for 24 h at 50 μM, and NTP formation was measured and quantified as 
previously described (Figure 2b). In both cell lines, 2′diF-4′N3-C levels were highest, 
followed by R1479 and then 2′F-4′N3-C, but higher overall NTP levels of all 3 nucleosides 
were seen in NCI-H358 cells. In light of these results, we decided to use NCI-H358 cells for 
our cell-based viral infection assays.
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3.3. R1479, 2′F-4′N3-C, and 2′diF-4′N3-C show minimal cytotoxicity in NCI-H358 cells
To ensure that the antiviral effects we observed in this study were not due to any cytotoxic 
effects attributed to the compounds themselves, we measured the viability of NCI-H358 
cells continually incubated with varying dilutions of each compound for 3 and 7 days 
(Figure 3). All 3 compounds produced low cytotoxicity 3 days post treatment, and R1479 
and 2′diF-4′N3-C resulted only in mild cytotoxicity at the highest concentration used (100 
μM) after 7 days of treatment (Figure 4b). Even 7 days post treatment, 50% cell cytotoxicity 
(CC50) levels were not reached.
3.4. 2′F-4′N3-C and 2′diF-4′N3-C show superior antiviral activity compared to R1479 
against recombinant reporter NiV, RSV, measles virus, and human parainfluenza virus 3
We initially evaluated the antiviral activity of R1479, 2′F-4′N3-C, and 2′diF-4′N3-C against 
recombinant reporter RSV (rgRSV224; (Hallak et al., 2000), measles virus 
(rMVEZEGFP(3); (Rennick et al., 2015), human parainfluenza virus-3 (hPIV3-GFP; (Zhang 
et al., 2005), and NiV (NiV-GFP2AM, (Lo et al., 2014) expressing green fluorescent 
reporter proteins (Figure 4). Whereas EC50 values for R1479 against all 4 viruses were 
consistently in the single-digit micromolar range, both 2′F-4′N3-C and 2′diF-4′N3-C 
inhibited each virus 3- to 20-fold more potently than R1479 (Table 1). 2′F-4′N3-C and 
2′diF-4′N3-C inhibited rgRSV224 and rMVEZEGFP(3) at similar concentrations (Table 1), 
but 2′F-4′N3-C was measurably more potent than 2′diF-4′N3-C against hPIV3-GFP 
(Figure 4c, Table 1). 2′F-4′N3-C also inhibited NiV-GFP2AM moderately more strongly 
than 2′diF-4′N3-C as measured by both a GFP reporter assay (Figure 4d) and CPE 
inhibition assay (data not shown; Table 1).
3.5. 2′F-4′N3-C and 2′diF-4′N3-C reduce both henipavirus-induced CPE and infectious 
virus yield more strongly than does R1479
We further evaluated the antiviral activity of 2′F-4′N3-C and 2′diF-4′N3-C against wild-
type NiV and HeV by measuring the inhibition of henipavirus-induced CPE and infectious 
virus yield (Figure 5). Similar to what was observed for NiV-GFP2AM, 2′F-4′N3-C and 
2′diF-4′N3-C inhibited NiV- and HeV-induced CPE with significantly greater potency than 
R1479, with 2′F-4′N3-C being marginally more potent than 2′diF-4′N3-C (Figure 5a, b). 
Accordingly, ~1.5 μM 2′F-4′N3-C and ~3 μM 2′diF-4′N3-C reduced infectious henipavirus 
yields by 4–5 orders of magnitude (Figure 5c, d), whereas 6–10 μM R1479 was required for 
similar virus yield reduction (Hotard et al., 2017). Although in this assay, EC50 values for 
2′F-4′N3-C and 2′diF-4′N3-C were identical against HeV and were within 3-fold against 
NiV (Table 1), 2′F-4′N3-C caused a sharper decline in both NiV and HeV titers than did 
2′diF-4′N3-C (Figure 5c, d).
3.6. EBOV variants are susceptible to inhibition by R1479 and 2′diF-4′N3-C, but are less 
susceptible to 2′F-4′N3-C inhibition
Recent work describing the broad-spectrum activity of adenosine nucleotide analog 
GS-5734 across Paramyxoviridae, Pneumoviridae, and Filoviridae families documented 
conserved amino acids in the nucleotide-binding domains of polymerases of these viruses, 
which may explain their susceptibility to similar compounds (Lo et al., 2017). In light of this 
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work, alongside other studies documenting the antiviral activity of R1479, 2′F-4′N3-C, and 
2′diF-4′N3-C against both HCV and RSV (Deval et al., 2015; Klumpp et al., 2006; Smith et 
al., 2009; Smith et al., 2007; Wang et al., 2015), we tested the antiviral activities of these 
compounds against recombinant reporter Mayinga and Makona EBOV variants (genus 
Ebolavirus, species Zaire ebolavirus) expressing green fluorescent proteins (Albarino et al., 
2015; Towner et al., 2005) (Figure 6a, b). R1479 and 2′diF-4′N3-C inhibited both EBOV 
variants similarly to henipaviruses, with approximate EC50 values of 2 μM and 0.3 μM, 
respectively (Table 1). In contrast to what was observed for henipaviruses, however, 
2′F-4′N3-C was 10 times less potent against EBOV, with EC50 values ranging from 3–8 μM 
(Table 1). All 3 compounds only negligibly inhibited a reporter RVFV, which belongs to the 
family Phenuiviridae, outside of the order Mononegavirales (Figure 6c).
To confirm our observations, we tested the compounds against wild-type EBOV (Makona 
variant) and measured their inhibition of EBOV infection and spread. By using an image-
based plate reader, we quantified EBOV infection by the percentage of EBOV antigen-
positive focus-forming units (FFUs) detected (Figure 6d–e). We observed dose-dependent 
inhibition of FFU formation with R1479 and 2′diF-4′N3-C treatment, but did not detect 
significant inhibition by 2′F-4′N3-C (Figure 6d, Table 1).
3.7. R1479 and 2′diF-4′N3-C potently inhibit SUDV
We then tested the 3 compounds against the Gulu variant of SUDV (genus Ebolavirus, 
species Sudan ebolavirus), a phylogenetically divergent relative of EBOV which prior to 
2014 was responsible for the largest filovirus outbreak in humans (Lamunu et al., 2004; 
Sanchez and Rollin, 2005). R1479 and 2′diF-4′N3-C inhibited SUDV with efficacy similar 
to that observed with EBOVs by the FFU assay (Figure 7a), with EC50 values of 2.5 μM 
(R1479) and 0.7 μM (2′diF-4′N3-C). Accordingly, 2′F-4′N3-C inhibited SUDV less 
potently than the other compounds, with an EC50 value of approximately 10 μM (Table 1). 
We further evaluated the antiviral activity of these 3 cytidine analogs against SUDV by 
measuring infectious virus yield (Figure 7b). Both R1479 and 2′diF-4′N3-C reduced 
infectious SUDV titers by > 4 orders of magnitude at concentrations of 25 μM and 6.25 μM, 
respectively, with respective EC50 values of 0.92 μM and 0.16 μM. On the other hand, 
2′F-4′N3-C only reduced infectious virus yield by approximately 1.5 orders of magnitude at 
the highest concentration used in the assay (12.5 μM) (Figure 7b).
3.8. R1479 and 2′diF-4′N3-C potently inhibit RAVV
Having determined the antiviral activity of these compounds against phylogenetically 
divergent members of the genus Ebolavirus, we proceeded to test them against another 
filovirus, Ravn virus (RAVV) (genus Marburgvirus, species Marburg marburgvirus), which, 
when compared with EBOV and SUDV, was determined to be the most phylogenetically 
divergent member of the genus Marburgvirus (~ 67–68% nucleotide divergence) (Towner et 
al., 2006). Using our FFU assay, we observed that R1479 inhibited RAVV with 3-fold lower 
potency than EBOV or SUDV, with an EC50 value of 7.4 μM. (Figure 8a, Table 1). 
2′diF-4′N3-C and 2′F-4′N3-C, however, inhibited RAVV similarly to EBOV and SUDV, 
with EC50 values of 0.73 μM and 10.8 μM, respectively. We then measured infectious RAVV 
production in the presence of the 3 compounds. Similar to what we observed for SUDV, both 
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R1479 and 2′diF-4′N3-C reduced infectious RAVV titers by over 4 orders of magnitude at 
concentrations of 50 μM and 6.25 μM, respectively, with respective EC50 values of 3 μM 
(R1479) and 0.16 μM (2′diF-4′N3-C; Figure 8b, Table 1). 2′F-4′N3-C reduced RAVV titers 
by roughly 1.5 orders of magnitude at the highest concentration used (25 μM), with an EC50 
value of 6 μM (Figure 8b, Table 1).
3.9. 2′F-4′N3-C potently inhibits NiV in human primary small airway epithelial cells
To verify the antiviral activity observed in the NCI-H358 cell line, we performed reporter 
and CPE assays for NiV using human primary small airway epithelial cells (SAECs), which 
have been shown to support robust NiV replication (Escaffre et al., 2013). For both the 
reporter and CPE assays which utilized the recombinant reporter NiV-GFP2AM virus, we 
observed potent inhibition by 2′F-4′N3-C, with respective EC50 values of 0.34 and 0.56 μM 
(Figure 9a–b, Table 2). The inhibition of both GFP and CPE could be visually observed, as 
treatment with 2′F-4′N3-C at 1.56 μM completely abolished GFP expression as well as CPE 
in the SAECs (Figure 9c). On the other hand, we observed markedly lower antiviral activity 
for R1479 and 2′diF-4′N3-C, which indicates that their respective intracellular NTP levels 
were likely lower than their levels observed in NCI-H358 cells.
3.10. 2′diF-4′N3-C inhibits Marburg virus infection in human primary small airway epithelial 
cells
Since filovirus-pseudotyped lentiviruses can efficiently transduce airway epithelial cells in 
vivo (Kobinger et al., 2001), we proceeded to evaluate the antiviral activities of these 
nucleosides in SAECs against a reporter Marburg virus (MARV-ZsG) expressing a green 
fluorescent protein. In cells treated with serial dilutions of 2′diF-4′N3-C, we observed a 
dose-dependent inhibition of MARV infection by FFU assay; whereas R1479 and 2′F-4′N3-
C did not show any significant inhibition (Figure 10a–b, Table 2). The comparatively higher 
EC50 value for 2′diF-4′N3-C against MARV-ZsG in SAECs (3.59 μM) than what was 
observed for RAVV in NCI-H358 cells (0.73 μM) is likely due to lower intracellular NTP 
levels.
4. DISCUSSION
In this study, we characterized the antiviral properties of R1479 and its analogs 2′F-4′N3-C 
and 2′diF-4′N3-C using both cell-free and cell-based assays. Despite the presence of 3′-OH 
group in each analog, all 3 compounds behaved like conventional non-obligatory RNA 
synthesis chain terminators in cell-free RSV polymerase assays (Deval et al., 2015). In order 
for nucleoside analogs to retain their antiviral function inside a cell, multiple cellular kinases 
are required to convert them to the active triphosphate form (Ray and Hitchcock, 2009). To 
better understand the cell type-dependent variability we previously observed with R1479 
antiviral activity (Hotard et al., 2017), we measured cellular levels of R1479-TP in 4 
different cell lines, and observed 2 to 3-fold higher levels of R1479-TP, 2′F-4′N3-CTP, and 
2′diF-4′N3-CTP in NCI-H358 cells than in HeLa cells. The comparatively elevated NTP 
levels observed in NCI-H358 cells may be attributed to higher expression levels of uridine-
cytidine kinases, which catalyze the presumed initial rate-limiting step of phosphorylating 
uridine and cytidine nucleosides (Van Rompay et al., 2001). Characterizing the NCI-H358 
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cell line as the optimal line to use in this study highlights the importance of confirming 
cellular triphosphate levels when conducting antiviral screens of nucleoside analog libraries. 
We have observed significantly decreased antiviral activity for R1479, 2′F-4′ N3-C, and 
2′diF-4′N3-C in Huh7 cells against reporter EBOVs (data not shown), which is likely 
explained by overall lower phosphorylation levels of these cytidine analogs in this cell line 
(Figure 2a). The higher potency of 2′F-4′N3-C, and 2′diF-4′N3-C over R1479 against 
paramyxoviruses, however, cannot solely be attributed to NTP levels, since R1479-TP levels 
were higher than 2′F-4′N3-CTP levels in these cells (Figure 2b). Moreover, the change in 
rank order of anti-filoviral potency in the cell-based assays suggests that the differences in 
antiviral activity are due to differential recognition, or discrimination, of these NTP analogs 
by viral polymerases. Our gel-based biochemical assay using RSV polymerase provides 
qualitative results and informs mainly on the mechanism of action of each compound, 
demonstrating substrate recognition and chain termination (Figure 1). It does not provide 
enough information to rank order potencies and/or discrimination between the three 
nucleotides (Deval et al., 2015). Evaluation of these compounds in primary human SAECs 
confirmed the potent anti-NiV activity of 2′F-4′N3-C (Figure 9) and the anti-MARV activity 
of 2′diF-4′N3-C (Figure 10). Our study did not include two other related nucleosides 2′ ′-
deoxy-2′-β-fluoro-4′-azidocytidine (RO-0622) and 2′-deoxy-2′-β-hydroxy-4′-
azidocytidine (RO-9187) (Klumpp et al., 2008) because they had little to no antiviral activity 
against both NiV and EBOV, respectively (data not shown). Our results warrant further 
studies comparing the antiviral potency of these NTP analogs against recombinant 
paramyxovirus and filovirus polymerases, although technical challenges have precluded 
such work only until very recently (Jordan et al., 2018). The ability of these cytidine analogs 
to reduce henipavirus and filovirus infectious yields by over 4 log TCID50/mL mirrors viral 
inhibition by GS-441524 (a 1′-cyano-modified adenosine analog) and its phosphoramidate 
nucleotide prodrug GS-5734 (Lo et al., 2017). GS-5734 inhibited filoviruses and 
coronaviruses in non-human primate and mouse models, respectively, and is currently in 
phase 2 clinical trials for treatment of EBOV disease (EVD) (Sheahan et al., 2017; Warren et 
al., 2016). Favipiravir, also known at T-705, is a broad-spectrum small molecule nucleoside 
precursor originally developed to treat influenza A virus; it also decreased EBOV infectious 
yield by 4 logTCID50/mL, albeit at high concentrations (1000 μM) by a yet-undefined 
mechanism (Baranovich et al., 2013; Oestereich et al., 2014). BCX4430 is an adenosine 
nucleoside analog with variable in vitro broad-spectrum activity across 8 virus families 
including Filoviridae, and is currently in phase 1 clinical trials for treating EVD (Taylor et 
al., 2016; Warren et al., 2014). Although BCX4430 inhibits HCV polymerase similarly to 
conventional chain terminators and also reduces infectious filovirus yield, its mechanism of 
action against negative-strand viruses is unclear. While neither R1479 nor its 2′-fluoro-
modified analogs are viable candidates for antiviral therapeutics due to variable 
incorporation by host mitochondrial RNA and DNA polymerases (Arnold et al., 2012; 
Clarke et al., 2015), they provide an initial comparison of filo- and paramyxovirus 
susceptibility to 4′-modified nucleosides. Our study provides evidence supporting the 
development of 4′-modified nucleosides with near-equivalent potency not only against 3 
Mononegavirales order families, but also against the positive-sense Flaviviridae family. 
Developing a small-molecule, broad-spectrum therapeutic to treat phylogenetically divergent 
viral infections that share significant epidemiological and clinical overlap (e.g., EBOV and 
Lo et al. Page 10
Antiviral Res. Author manuscript; available in PMC 2018 July 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
yellow fever virus; NiV and Japanese encephalitis virus) would benefit clinicians with no 
access to rapid diagnostics amidst an outbreak of these serious viral infections.
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Figure 1. 
Inhibition of RSV polymerase activity by 4′-modified cytidine analogs. Chemical structures 
of (a) 4′-azidocytidine (R1479), (b) 2′-monofluoro-4′-azidocytidine (2′F-N3-C), and (c) 2′-
difluoro-4′-azidocytidine (2′diF-4′N3-C). (d) Schematic of template-directed primer (5′-
ACGC) extension assay. *G above the red arrow indicates radioactively labeled guanosine 
triphosphate (GTP). Similarly, A and C above the red arrow indicate triphosphorylated 
forms of adenosine (ATP) and cytidine (CTP), respectively. Numbers specify nucleotide 
positions relative to the first nucleotide of the final primer extension product. (e). Primer 
extension assay performed with the presence of 33P-radiolabeled GTP alone (lane 1), with 
ATP (lane 2), and with varying combinations of CTP (lane 3), R1479-TP (lane 4), 2′F-4′N3-
CTP (lane 5), or 2′diF-4′N3-CTP (lane 6), as indicated by + and - signs.
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Figure 2. 
Quantification and comparison of cellular nucleoside triphosphate (TP) levels of R1479, 
2′F-4′N3-C, and 2′diF-4′N3-C. (a). R1479-TP levels were measured in 4 different cell 
types (HeLa, Huh7, SK-N-MC, and NCI-H358) after 24 h of treatment at 50 μM. (b) Levels 
of triphosphorylated R1479, 2′F-4′N3-C, and 2′diF-4′N3-C in HeLa cells (black bars) and 
NCI-H358 cells (gray bars) after 24 h of treatment at 50 μM. Graphs and error bars indicate 
mean values and standard deviations for each compound in each cell line performed at 
minimum in biological triplicates.
Lo et al. Page 16
Antiviral Res. Author manuscript; available in PMC 2018 July 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
R1479, 2′F-4′N3-C, and 2′diF-4′N3-C do not cause significant cell cytotoxicity. 
Representative dose response curves measuring cell viability of uninfected cells treated with 
R1479 (green circles), 2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) 
measured at (a) 72 h post treatment or (b) 168 hours post treatment. Cell viability was 
measured using CellTiter-Glo 2.0 assay reagent. Luminescence levels (indicative of cellular 
ATP levels as a surrogate marker of cell viability) assayed in DMSO-treated, uninfected 
cells were set as 100% cell viability. Dose response curves were fitted to the mean value of 
experiments performed in quadruplicate for each concentration in the 10-point 3-fold 
dilution series using a 4-parameter non-linear logistic regression curve with variable slope. 
Viability assay was repeated once for the 72 h time point.
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Figure 4. 
Antiviral activity of R1479, 2″F-4′N3-C, and 2′diF-4′N3-C against reporter pneumo- and 
paramyxoviruses. Representative dose response curves for R1479 (green circles), 2′F-4′N3-
C (blue triangles), and 2′diF-4′N3-C (red squares) against recombinant reporter (a) 
respiratory syncytial virus (rgRSV224), (b) measles virus (rMVEZ(3)GFP), (c) human 
parainfluenza virus 3 (hPIV3-GFP), and (d) Nipah virus (NiV-GFP2AM). Data points and 
error bars indicate the mean value and standard deviation of 4 biological replicates, and are 
representative of at least 2 independent experiments for each compound.
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Figure 5. 
R1479, 2′F-4′N3-C, and 2′diF-4′N3-C reduce henipavirus cytopathic effect (CPE) and 
infectious virus yield. Representative dose response curves for R1479 (green circles), 
2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) against wild-type (a) NiV and 
(b) Hendra virus (HeV) as measured by CPE determination. CPE assays were independently 
repeated at least 3 times for each compound for both NiV and HeV. Reduction of infectious 
NiV (c) and HeV (d) yield by 2′F-4′N3-C and 2′diF-4′N3-C. TCID50/mL values (in log 
scale) for each data point represent the mean of triplicate (2′diF-4′N3-C) or quadruplicate 
(2′F-4′N3-C) infection experiments for each concentration in the 10-point, 3-fold dilution 
series of each compound performed once. Dotted line indicates limit of detection. Error bars 
indicate standard deviation of the mean values.
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Figure 6. 
R1479, 2′F-4′N3-C, and 2′diF-4′N3-C inhibit Ebola virus (EBOV) variants but not Rift 
Valley fever virus (RVFV). Representative dose-response curves for R1479 (green circles), 
2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) against recombinant reporter 
(a) EBOV-Mayinga variant, (b) EBOV-Makona variant, and (c) RVFV expressing green 
fluorescent proteins. (d) Representative dose-response curves of the same compounds 
against wild-type EBOV (2014 Makona variant) using a focus forming unit (FFU) assay. 
FFU assays against EBOV were repeated once for R1479, twice for 2′diF-4′N3-C, and was 
performed once for 2′F-4′N3-C. (e) Representative composite micrographs of FFU assays in 
individual wells of a 96-well plate of R1479-treated, EBOV-infected, formalin-inactivated 
NCI-H358 cells stained with anti-EBOV polyclonal sera and Dylight-488 conjugated 
secondary antibody. Concentrations of R1479 (in μM) are indicated above each pictured 
well.
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Figure 7. 
R1479, 2′F-4′N3-C, and 2′diF-4′N3-C inhibit Sudan virus (SUDV). (a) Representative 
dose-response curves for R1479 (green circles), 2′F-4′N3-C (blue triangles), and 
2′diF-4′N3-C (red squares) against SUDV (Gulu variant) using a focus forming unit (FFU) 
assay. FFU assays for R1479 and 2′F-4′N3-C were performed once, and was repeated once 
for 2′diF-4′N3-C. (b) Reduction of infectious SUDV yield (in log scale) by R1479, 
2′diF-4′N3-C, and 2′F-4′N3-C. TCID50/mL values (in log scale) for each data point 
represent the mean of quadruplicate infections for each concentration in the 10-point, 3-fold 
dilution series for each compound performed once.
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Figure 8. 
R1479, 2′F-4′N3-C, and 2′diF-4′N3-C inhibit Marburgvirus Ravn virus (RAVV). (a) 
Representative dose-response curves of R1479 (green circles), 2′F-4′N3-C (blue triangles), 
and 2′diF-4′N3-C (red squares) against RAVV using an FFU assay. FFU assays were 
independently repeated four times for R1479, twice for 2′F-4′N3-C, and three times for 
2′diF-4′N3-C. Dose response curves were fitted to the mean value of experiments 
performed in quadruplicate for each concentration in the 10-point, 3-fold dilution series 
using a 4-parameter non-linear logistic regression curve with variable slope. (b) Reduction 
of infectious RAVV yield (in log scale) by R1479, 2′diF-4′N3-C, and 2′F-4′N3-C. 
TCID50/mL values for each data point represent the mean of quadruplicate infections for 
each concentration in the 10-point, 3-fold dilution series of each compound performed once.
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Figure 9. 
2′F-4′N3-C potently inhibits reporter NiV gene expression (GFP) and cytopathic effect 
(CPE) in human primary small airway epithelial cells. Representative dose response curves 
for R1479 (green circles), 2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) 
against recombinant reporter NiV (NiVGFP2AM) by measuring (a) GFP expression at 48 
hours post-infection, and by measuring (b) CPE inhibition at 72 hours post-infection. Data 
points and error bars indicate the mean value and standard deviation of 4 biological 
replicates. (c) Bright field (BF) and fluorescence (GFP) microscopy of uninfected control, 
DMSO treated NiV-GFP2AM infected control, and 2′F-4′N3-C treated NiV-GFP2AM 
infected SAECs. Concentration of 2′F-4′N3-C is indicated in μM. White bar indicates 
distance of 500 μm.
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Figure 10. 
2′diF-4′N3-C inhibits reporter Marburg virus (MARV) infection in human primary small 
airway epithelial cells. (a) Representative dose response curves for R1479 (green circles), 
2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) against recombinant reporter 
MARV expressing a green fluorescent protein (ZsGreen1) using a focus forming unit (FFU) 
assay. FFU assays for R1479 and 2′F-4′N3-C were performed once, and was repeated once 
for 2′diF-4′N3-C. Data points and error bars indicate the mean value and standard deviation 
of 4 biological replicates. (b) Representative composite micrographs of MARV GFP+ FFUs 
in individual wells of a 96-well plate of 2′diF-4′N3-C -treated, MARV-infected SAECs. 
Concentrations of 2′diF-4′N3-C (in μM) are indicated above each pictured well.
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